CareDx, Inc. (CDNA)
NASDAQ: CDNA · Real-Time Price · USD
21.91
+0.06 (0.27%)
At close: Apr 28, 2026, 4:00 PM EDT
21.40
-0.51 (-2.33%)
After-hours: Apr 28, 2026, 4:13 PM EDT
CareDx Revenue
In the year 2025, CareDx had annual revenue of $379.81M with 13.79% growth. CareDx had revenue of $108.39M in the quarter ending December 31, 2025, with 25.19% growth.
Revenue (ttm)
$379.81M
Revenue Growth
+13.79%
P/S Ratio
2.95
Revenue / Employee
$496,477
Employees
765
Market Cap
1.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 379.81M | 46.02M | 13.79% |
| Dec 31, 2024 | 333.79M | 53.46M | 19.07% |
| Dec 31, 2023 | 280.32M | -41.47M | -12.89% |
| Dec 31, 2022 | 321.79M | 25.40M | 8.57% |
| Dec 31, 2021 | 296.40M | 104.20M | 54.22% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| Twist Bioscience | 391.56M |
| Castle Biosciences | 344.23M |
| Fulgent Genetics | 322.67M |
CDNA News
- 17 minutes ago - CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing - Business Wire
- 21 minutes ago - CareDx Announces First Quarter 2026 Financial Results - Business Wire
- 7 days ago - CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting - Business Wire
- 8 days ago - CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing - Business Wire
- 12 days ago - CareDx Sharpens Focus On Core Testing Services - Benzinga
- 12 days ago - Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division - GlobeNewsWire
- 12 days ago - CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results - Business Wire
- 14 days ago - CareDx to Report First Quarter 2026 Financial Results on April 28, 2026 - Business Wire